Orexin
What the Research Actually Shows
Human: 3 studies, 5 groups · Animal: 0 · In Vitro: 0
The neuropeptide that keeps you awake—whose loss causes narcolepsy, whose blockade treats insomnia with three FDA-approved drugs, and whose replacement could be the next breakthrough in sleep medicine
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Orexin is the peptide that keeps you awake. About 70,000 neurons in your brain produce it, and they fire when you are alert, exploring, eating, or motivated. When those neurons are destroyed—as happens in narcolepsy type 1—people fall asleep uncontrollably and lose muscle tone during strong emotions. Three FDA-approved drugs (suvorexant, lemborexant, daridorexant) work by blocking orexin receptors to treat insomnia. These drugs are not the peptide itself—they are small molecules that target the orexin system. The biology is one of the clearest peptide-disease links in medicine: lose orexin neurons, get narcolepsy. Block orexin receptors, fall asleep. Companies are now developing orexin receptor activators to replace what narcolepsy patients have lost.
In 1998, two laboratories independently discovered the same neuropeptide system and gave it two names. Masashi Yanagisawa's group at UT Southwestern called the peptides "orexins" (from the Greek orexis, appetite) because injecting them into rat brains stimulated feeding. Luis de Lecea's group at Scripps called them "hypocretins" (hypothalamic secretin-like peptides) because they identified them through subtractive cloning of hypothalamus-enriched mRNAs. Both names persist in the literature. Both refer to two peptides—orexin-A (33 amino acids, two disulfide bonds) and orexin-B (28 amino acids, linear)—produced exclusively by a small cluster of roughly 70,000 neurons in the lateral hypothalamus.
Within two years of discovery, two findings transformed orexin from a feeding peptide into a sleep-medicine keystone. First, dogs with a mutation in the orexin receptor gene (OX2R) developed narcolepsy (Lin et al., 1999). Second, human narcolepsy type 1 patients had undetectable cerebrospinal fluid orexin-A levels (Nishino et al., 2000; PMID 10880529), later shown to result from autoimmune destruction of orexin-producing neurons. This made narcolepsy type 1 one of the few neurological diseases with a known single-molecule cause—and orexin became the most clinically consequential neuropeptide discovery of the modern era.
The therapeutic implications followed rapidly. Three dual orexin receptor antagonists (DORAs)—suvorexant (Belsomra, 2014), lemborexant (Dayvigo, 2019), and daridorexant (Quviviq, 2022)—are now FDA-approved for insomnia, creating an entirely new drug class. Orexin receptor agonists for narcolepsy are in clinical development. This article examines the peptide system behind these drugs, what its loss means for narcolepsy patients, and why the orexin story represents the clearest bench-to-bedside success in neuropeptide biology.
In This Article
Quick Facts: Orexin at a Glance
Type
Neuropeptide pair: Orexin-A (33 amino acids, cyclic with two disulfide bonds) and Orexin-B (28 amino acids, linear). Also called hypocretin-1 and hypocretin-2.
Also Known As
Hypocretin (Hcrt), Orexin-A/OxA/Hcrt-1, Orexin-B/OxB/Hcrt-2
Generic Name
No orexin peptide drug approved. DORAs: suvorexant, lemborexant, daridorexant (small molecules targeting orexin receptors).
Route
DORAs: oral tablets (10–50 mg depending on drug). Orexin peptides: IV infusion (research), intracerebroventricular (animal models). No subcutaneous or intranasal orexin peptide protocols established. Orexin-A has limited BBB penetration; orexin-B essentially none.
Molecular Weight
Orexin-A: ~3,562 Da. Orexin-B: ~2,937 Da.
Peptide Sequence
Orexin-A: 33 amino acids with N-terminal pyroglutamyl and two intrachain disulfide bonds (Cys6–Cys12, Cys7–Cys14). Orexin-B: 28 amino acids, linear, 46% sequence homology with OxA. Both derived from a single 131-amino-acid precursor (prepro-orexin).
Endogenous Origin
Yes. Produced exclusively by approximately 70,000 neurons in the lateral hypothalamus (LH) and perifornical area. These neurons project throughout the entire CNS—one of the most widespread projection systems of any neuropeptide.
Primary Molecular Function
OxA binds both OX1R (Gq-coupled, selective) and OX2R (Gq/Gi-coupled). OxB binds OX2R with equal affinity to OxA but has 10-fold lower OX1R affinity. Receptor activation on wake-promoting neurons (locus coeruleus, tuberomammillary nucleus, raphe nuclei, VTA) → sustained wakefulness. OX2R is the critical receptor for wake maintenance.
Active Fragment
Full-length OxA and OxB are the primary active forms. OxA's disulfide bonds confer greater stability (plasma half-life ~30 minutes vs. ~5 minutes for OxB). OxA crosses the blood-brain barrier to a limited degree; OxB does not.
Brand Name
Belsomra (suvorexant), Dayvigo (lemborexant), Quviviq (daridorexant) — all insomnia drugs that block orexin receptors
Related Compound Relationship
CRH (also in Cluster J) activates orexin neurons during stress-induced arousal—the CRH→orexin→wake pathway is one mechanism linking stress to insomnia. MCH (also in Cluster J) is produced by neighboring neurons in the lateral hypothalamus and promotes REM sleep, opposing orexin's wake-promoting function.
Clinical Programs
Three DORAs approved (2014–2022). Orexin receptor agonists in development: TAK-994 (Takeda, oral OX2R agonist for narcolepsy—Phase II halted for safety signals, 2022; successor TAK-861 in Phase II). Firazorexant (Eisai, oral DORA-class). Gene therapy approaches for orexin neuron replacement under preclinical investigation.
FDA Status
Three DORAs FDA-approved for insomnia: suvorexant (2014), lemborexant (2019), daridorexant (2022). All Schedule IV controlled substances. Orexin peptides not approved therapeutically. Orexin agonists in clinical development.
WADA Status
Orexin peptides: not on the Prohibited List. DORAs: not currently prohibited but monitored—sleep manipulation via pharmacological agents is an area of increasing anti-doping scrutiny.
Community Interest
Moderate conceptual interest. DORAs are prescription insomnia medications discussed in sleep-optimization and biohacking communities as alternatives to benzodiazepines and Z-drugs. Orexin peptides themselves are not available from consumer vendors. The narcolepsy-orexin connection generates interest in neuroscience-engaged communities.
Half-Life
Orexin-A: ~30 minutes in plasma (protected by disulfide bonds). Orexin-B: ~5 minutes (linear, rapidly degraded). DORAs: suvorexant 12 hours, lemborexant ~17–19 hours, daridorexant ~8 hours.
Evidence Tier
1 Approved Drug
Verdict
Strong Foundation
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Orexin?
Pronunciation: oh-REX-in
In the lateral hypothalamus of the human brain, a cluster of about 70,000 neurons does something no other cell population does: it keeps you awake. These neurons produce two peptides—orexin-A and orexin-B—and project their axons to virtually every major arousal center in the brain. When these neurons fire, you are alert, motivated, hungry, and engaged. When they go silent, you sleep. When they are destroyed, you have narcolepsy.
The orexin system was discovered twice, simultaneously, in 1998. Masashi Yanagisawa's group at UT Southwestern found the peptides through an orphan receptor screening strategy and named them orexins because injecting them into rats stimulated feeding (Sakurai et al., 1998; PMID 9491897). Luis de Lecea's group at Scripps identified the same molecules through hypothalamus-enriched gene expression and called them hypocretins. Both names survive in the literature—"orexin" has become dominant in sleep medicine and pharmacology, "hypocretin" in some neuroscience contexts—and they refer to the same two peptides.
Within two years of discovery, orexin went from "an interesting appetite peptide" to "the cause of narcolepsy"—one of the fastest and most definitive disease-mechanism connections in the history of neuroscience. By 2014, the first drug targeting the orexin system was approved. By 2022, three were on the market. The orexin story is not a cautionary tale of failed translation. It is the blueprint for how neuropeptide biology should work.
PLAIN ENGLISH
About 70,000 brain cells in a region called the lateral hypothalamus produce orexin—a pair of peptides that act like a master switch for wakefulness. When those cells are active, you are awake and alert. When they are destroyed by the immune system, the result is narcolepsy—a condition where people cannot stay awake and sometimes collapse during strong emotions. Three prescription sleep medications (suvorexant, lemborexant, daridorexant) work by temporarily blocking orexin's receptors to help people with insomnia fall asleep.
Origins and Discovery
The orexin discovery has a favorite detail in the history of science: two independent laboratories, using entirely different experimental strategies, found the same molecule in the same year and gave it different names. In January 1998, de Lecea published the identification of hypocretin mRNAs enriched in the lateral hypothalamus. In February 1998, Sakurai published the orexin peptides and their receptors, discovered by screening orphan G-protein-coupled receptors for their natural ligands.
Both groups initially focused on appetite—orexin stimulated feeding when injected into rat brains, and the lateral hypothalamus had long been associated with feeding behavior. (Lesioning this region in rats produced animals that refused to eat.) But the appetite angle was a misdirection. The real story emerged in 1999 when Lin et al. demonstrated that narcoleptic Doberman pinschers carried a mutation in the orexin-2 receptor gene (OX2R). Within months, Chemelli et al. showed that orexin-knockout mice developed narcolepsy-like symptoms. And in 2000, Nishino et al. measured undetectable CSF orexin-A in human narcolepsy type 1 patients (PMID 10880529).
The speed was extraordinary. From discovery to disease mechanism in 24 months. From disease mechanism to approved drug in 16 years (suvorexant, 2014). The pivot from "appetite peptide" to "wakefulness peptide" happened because the science was followed honestly—when the feeding effects turned out to be secondary to the arousal effects, the field recalibrated.
PLAIN ENGLISH
Two labs found orexin independently in 1998—one looking for hypothalamus genes, the other screening for receptor ligands. They initially thought it was about appetite. Then dogs with an orexin receptor mutation turned out to have narcolepsy. Then human narcolepsy patients turned out to have no orexin in their spinal fluid. In two years, orexin went from unknown peptide to the proven cause of narcolepsy—and within 16 years, the first drug targeting it was on the market.
Mechanism of Action
The Wake-Promoting System
Orexin neurons in the lateral hypothalamus serve as a stabilizer for the sleep-wake "flip-flop switch"—a concept developed by Clifford Saper at Harvard. The model:
Wake-promoting nuclei (locus coeruleus/norepinephrine, tuberomammillary nucleus/histamine, raphe nuclei/serotonin, ventral tegmental area/dopamine) and sleep-promoting nuclei (ventrolateral preoptic area/GABA) mutually inhibit each other. This creates a bistable switch—you are either awake or asleep, with rapid transitions between states. The orexin system stabilizes the "wake" position of this switch by providing tonic excitatory input to all wake-promoting nuclei.
Without orexin, the switch becomes unstable. Patients with narcolepsy type 1 experience sudden, inappropriate transitions from wake to sleep (sleep attacks) and from wake to REM-related states (cataplexy—loss of muscle tone during emotional triggers, hypnagogic hallucinations, sleep paralysis). The instability is not drowsiness—it is state boundary failure.
Receptor Pharmacology
OX1R: Selective for orexin-A (OxA binds with ~10× higher affinity than OxB). Gq-coupled → phospholipase C → intracellular calcium. Expressed in locus coeruleus (norepinephrine), VTA (dopamine). Implicated in reward-seeking behavior, stress-induced arousal, and motivation.
OX2R: Binds both OxA and OxB equally. Gq/Gi-coupled (dual signaling). Expressed in tuberomammillary nucleus (histamine), which is the single most important target for wake maintenance. OX2R knockout produces narcolepsy in animals. This receptor is the primary therapeutic target for both insomnia (antagonism) and narcolepsy (agonism).
DORAs — Blocking Orexin for Insomnia
Dual orexin receptor antagonists block both OX1R and OX2R, temporarily reducing wake drive: - Suvorexant (Belsomra): First-in-class. 10–20 mg at bedtime. Long half-life (12 hours). Schedule IV. - Lemborexant (Dayvigo): 5–10 mg. Longer half-life (~17–19 hours). Balanced OX1R/OX2R affinity. - Daridorexant (Quviviq): 25–50 mg. Shorter half-life (~8 hours). Designed for less next-morning sedation. Also improved daytime functioning in trials—unique among DORAs.
Unlike benzodiazepines and Z-drugs, DORAs do not enhance GABA signaling. They produce sleep that more closely resembles natural sleep architecture, with preserved slow-wave and REM sleep. They do not cause respiratory depression—a critical advantage for patients with sleep apnea or obesity.
Orexin Agonists — The Emerging Frontier
If blocking orexin treats insomnia, replacing it should treat narcolepsy. This logic is driving the development of orexin receptor agonists: - TAK-994 (Takeda): Oral OX2R-selective agonist. Phase II for narcolepsy type 1. Showed dramatic improvement in wakefulness but was halted in 2022 due to hepatotoxicity signals. Successor TAK-861 is in Phase II with a modified structure. - Firazorexant and other OX2R agonists are in earlier-stage development.
PLAIN ENGLISH
Orexin works like a thumb holding down a toggle switch on the "awake" side. Without it, the switch flips randomly—you fall asleep without warning, sometimes collapse during laughter or surprise, and can slip into dream states while still partially awake. That is narcolepsy. The insomnia drugs (DORAs) work by temporarily lifting that thumb—blocking orexin receptors so the switch can flip to the sleep side. Unlike older sleep pills, they produce more natural sleep and do not suppress breathing. The next frontier is orexin replacement—a drug that restores the missing signal in narcolepsy patients.
Key Research Areas and Studies
Suvorexant Pivotal Trials (Herring et al., 2012)
Study: Phase III registration trials of suvorexant for insomnia. PMID: 23096513 Design: Two randomized, double-blind, placebo-controlled trials totaling 2,085 adults with insomnia disorder. Key findings: Suvorexant significantly improved both subjective and polysomnography-measured sleep onset latency and wake after sleep onset. Effects maintained over 3 months. Dose-dependent efficacy at 20 and 40 mg (FDA approved 10–20 mg after dose-cap negotiations). Significance: First-in-class DORA approval. Proved the concept that blocking orexin could treat insomnia without the GABA-mediated risks of benzodiazepines.
SUNRISE-1 — Lemborexant (Rosenberg et al., 2019)
Study: Phase III randomized trial of lemborexant vs. placebo and zolpidem for insomnia. PMID: 31583409 Design: 1,006 adults with insomnia. Three arms: lemborexant 5 mg, lemborexant 10 mg, zolpidem 6.25 mg extended-release, placebo. Polysomnography-measured endpoints. Key findings: Lemborexant at both doses was superior to placebo for sleep onset and wake after sleep onset. Lemborexant 10 mg was superior to zolpidem for sleep onset latency. First head-to-head demonstration of a DORA beating the market-leading Z-drug on a primary endpoint.
Daridorexant Phase III (Mignot et al., 2022)
Study: Phase III trials of daridorexant for insomnia. PMID: 35045290 Design: 1,854 adults with insomnia across two pivotal trials. 25 and 50 mg doses vs. placebo. Key findings: Dose-dependent improvement in sleep onset, sleep maintenance, and—uniquely among DORAs—daytime functioning as measured by the IDSIQ (Insomnia Daytime Symptoms and Impacts Questionnaire). 50 mg showed improvements on all three co-primary endpoints. Significance: First DORA to demonstrate improvement in daytime functioning, not just nighttime sleep. Shorter half-life (~8 hours) designed to reduce next-morning residual effects.
Orexin Deficiency in Narcolepsy (Nishino et al., 2000)
Study: Measurement of CSF hypocretin-1 (orexin-A) in narcolepsy and other neurological conditions. PMID: 10880529 Design: Lumbar puncture–based CSF sampling in 31 subjects (9 narcolepsy type 1, controls). Key findings: CSF orexin-A was undetectable (<40 pg/mL) in all narcolepsy type 1 patients. Normal levels in controls. Subsequently validated in hundreds of patients as a diagnostic biomarker (CSF orexin-A <110 pg/mL = diagnostic for narcolepsy type 1). Significance: Established the most definitive neuropeptide-disease link in medicine. Narcolepsy type 1 is not "associated with" orexin deficiency—it IS orexin deficiency.
Orexin Discovery (Sakurai et al., 1998)
Study: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. PMID: 9491897 Significance: Discovery paper. Identified orexin-A, orexin-B, OX1R, and OX2R. Initially characterized orexins as feeding peptides—the sleep-wake role emerged within the next two years.
PLAIN ENGLISH
Three large trials—testing three different orexin-blocking drugs in a total of nearly 5,000 insomnia patients—showed that blocking orexin receptors helps people fall asleep faster and stay asleep longer. The newest drug (daridorexant) also showed people felt better during the day, not just at night. On the narcolepsy side, a simple spinal fluid test showing absent orexin-A now diagnoses the disease—one of the few neurological conditions where a single missing molecule explains the entire clinical picture.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Orexin keeps you awake” | Orexin neurons fire during wakefulness and are silent during sleep. Orexin loss causes narcolepsy. Orexin receptor blockade (DORAs) produces sleep. Among the most thoroughly validated peptide-function relationships in neuroscience. | Supported |
| “Narcolepsy is caused by orexin loss” | Narcolepsy type 1 patients have >90% loss of orexin neurons and undetectable CSF orexin-A. The mechanism is autoimmune destruction, likely triggered by HLA-DQB1*06:02 and environmental factors (H1N1, Pandemrix). Definitive causal link. | Supported |
| “DORAs treat insomnia” | Three Phase III programs (suvorexant N=2,085; lemborexant N=1,006; daridorexant N=1,854) demonstrated significant improvement in sleep onset and maintenance. Three FDA-approved drugs. | Supported |
| “DORAs are safer than benzodiazepines” | DORAs do not cause respiratory depression (critical for sleep apnea patients), produce more physiological sleep architecture, and have lower abuse potential (Schedule IV vs. Schedule IV for benzos, but mechanistically different). Head-to-head safety comparisons are limited. | Supported with Caveat |
| “Orexin agonists will cure narcolepsy” | Orexin replacement is biologically rational and TAK-994 showed dramatic wakefulness improvement in Phase II. However, TAK-994 was halted for liver toxicity. TAK-861 is in Phase II. No orexin agonist is approved. "Will cure" is premature. | Mixed Evidence |
| “DORAs produce natural sleep” | DORAs preserve slow-wave and REM sleep architecture better than benzodiazepines and Z-drugs. "Natural" is relative—any pharmacological intervention alters sleep to some degree—but the architecture is closer to physiological than GABA-enhancing drugs. | Supported with Caveat |
| “Orexin supplements can improve wakefulness” | Orexin peptides do not cross the blood-brain barrier reliably after peripheral administration. No oral, injectable, or nasal orexin supplement has demonstrated wake-promoting effects in humans. The DORAs work because they are small molecules that penetrate the brain. | Unsupported |
| “Orexin is only about sleep” | Orexin neurons regulate appetite, reward-seeking, stress responses, autonomic function, and energy homeostasis in addition to sleep-wake cycling. The sleep role is clinically dominant but orexin is a broader arousal/motivation peptide. | Unsupported |
| “DORAs cause next-morning grogginess” | Suvorexant and lemborexant have longer half-lives and can produce residual morning effects. Daridorexant (~8-hour half-life) was designed to minimize this. Next-morning effects are dose- and compound-dependent, not a class effect. | Mixed Evidence |
| “Orexin testing can diagnose sleep disorders” | CSF orexin-A <110 pg/mL is diagnostic for narcolepsy type 1 (sensitivity >87%, specificity >99%). It does not diagnose insomnia, narcolepsy type 2, or other sleep disorders. Specific to narcolepsy type 1 with cataplexy. | Supported with Caveat |
| “Children can take DORAs” | Lemborexant is approved for adults ≥18. Suvorexant and daridorexant likewise. Pediatric trials are limited. DORAs are not currently approved for any pediatric indication. | Unsupported |
| “DORAs are addictive” | DORAs are Schedule IV (lower abuse potential than Schedule II stimulants or opioids). Clinical trials showed minimal rebound insomnia on discontinuation and low abuse liability in human abuse potential studies. Not considered addictive in clinical practice. | Unsupported |
The Human Evidence Landscape
The human evidence for the orexin system is among the strongest for any neuropeptide in the Peptidings universe—perhaps rivaled only by desmopressin (also in this cluster) and insulin. Three separate drug classes (three DORAs), nearly 5,000 patients across pivotal trials, a definitive disease link (narcolepsy), and an active agonist pipeline make orexin the gold standard for translational neuropeptide biology.
DORA Trials — Three Drugs, One Clear Message
The three DORA Phase III programs collectively enrolled nearly 5,000 insomnia patients across multiple randomized, double-blind, placebo-controlled trials with polysomnography-measured endpoints. The consistency is remarkable: all three drugs improved both sleep onset latency and wake after sleep onset. Lemborexant beat zolpidem head-to-head on a primary endpoint. Daridorexant uniquely improved daytime functioning—not just nighttime sleep—suggesting that the quality of DORA-induced sleep may be superior to that produced by GABA-enhancing drugs.
The DORA evidence base is not in the same category as most compounds on Peptidings. These are not pilot studies, not open-label observations, not community reports. They are FDA-registration-quality pivotal trials with objective endpoints, validated by the FDA review process three separate times.
Narcolepsy — The Definitive Neuropeptide Disease
The orexin-narcolepsy connection is one of the cleanest causal chains in medicine: specific autoimmune destruction of orexin neurons → >90% loss of orexin → CSF orexin-A undetectable → narcolepsy type 1 with cataplexy. The CSF orexin-A assay has >87% sensitivity and >99% specificity for narcolepsy type 1. No other neuropeptide disease has this level of diagnostic clarity.
The autoimmune mechanism is increasingly characterized: HLA-DQB1*06:02 (present in >98% of narcolepsy type 1 patients vs. ~25% of general population) confers susceptibility. Environmental triggers include H1N1 influenza infection and the Pandemrix vaccine (which caused a spike in narcolepsy cases in Scandinavian children during the 2009 pandemic). T-cell–mediated destruction of orexin neurons has been demonstrated.
Orexin Agonists — The Next Chapter
If DORAs proved that blocking orexin treats insomnia, the logical next step is proving that replacing orexin treats narcolepsy. TAK-994 (Takeda) was an oral OX2R-selective agonist that showed dramatic improvement in wakefulness measures in a Phase II narcolepsy trial—patients on TAK-994 showed wake maintenance similar to healthy controls. However, the program was halted in October 2022 after hepatotoxicity signals emerged. Takeda's successor compound, TAK-861, is in Phase II with structural modifications intended to avoid the liver liability.
The orexin agonist story is ongoing. The biology strongly supports the approach—restoring the missing signal should correct the disease—but the drug development challenges (achieving oral bioavailability for a peptide receptor agonist, avoiding off-target hepatotoxicity) are real. This is not a question of whether the mechanism works but whether a safe molecule can be found.
PLAIN ENGLISH
Three different orexin-blocking drugs tested in nearly 5,000 insomnia patients all showed the same thing: blocking orexin helps people sleep. One beat the most popular sleeping pill (zolpidem) head-to-head. Meanwhile, measuring orexin in spinal fluid can diagnose narcolepsy with 99% accuracy—one of the most reliable diagnostic tests in neurology. The next frontier is orexin replacement for narcolepsy. The first attempt (TAK-994) worked spectacularly for wakefulness but caused liver problems. A redesigned version is being tested now.
Safety, Risks, and Limitations
DORA Safety Profile
The three approved DORAs share a class safety profile that reflects orexin receptor blockade:
Common adverse effects (5–10%): - Somnolence (expected pharmacology—the drug is designed to cause sleepiness) - Headache - Dizziness - Fatigue
Orexin-specific effects (uncommon, 1–5%): - Sleep paralysis (inability to move during sleep-wake transitions—reflects temporary orexin system suppression mimicking a narcolepsy-like state) - Hypnagogic/hypnopompic hallucinations (vivid hallucinations during sleep onset or awakening) - Complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating—rare but FDA-labeled)
What DORAs do NOT cause: - Respiratory depression (critical advantage over benzodiazepines—makes DORAs safe in obstructive sleep apnea) - Cognitive impairment comparable to benzodiazepines - Significant rebound insomnia on discontinuation - Physical dependence at clinical doses
Labeling concerns: - Suicidal ideation: FDA labeling includes a warning, primarily based on theoretical concern and rare trial events rather than a demonstrated causal mechanism - Next-morning impairment: Possible with longer-acting compounds (suvorexant, lemborexant). Patients advised against driving until they know how they respond. Daridorexant's shorter half-life was designed to reduce this
Orexin Peptide Safety (Research Context)
IV orexin infusion in research settings produces transient cardiovascular effects (blood pressure increase, tachycardia) reflecting orexin's role in autonomic regulation. These are expected pharmacology, not safety concerns in a clinical setting. No safety profile exists for chronic orexin peptide administration in humans because it has not been done.
TAK-994 Hepatotoxicity
The hepatotoxicity signal that halted TAK-994 development is compound-specific—related to the molecule's structure—not mechanism-specific. Orexin receptor agonism per se is not expected to cause liver damage. TAK-861, the successor, has structural modifications designed to avoid this liability. The clinical community views orexin agonism as a viable therapeutic mechanism; the challenge is finding a safe molecule.
PLAIN ENGLISH
The insomnia drugs that block orexin are generally well tolerated—the main side effect is being sleepy, which is the point. They can occasionally cause sleep paralysis or vivid hallucinations during sleep transitions, which makes sense because they are temporarily mimicking a mild version of what narcolepsy patients experience. Unlike older sleeping pills, they do not suppress breathing—a major advantage for people with sleep apnea. The orexin-replacement drug for narcolepsy (TAK-994) worked for wakefulness but was toxic to the liver. That appears to be a molecule problem, not a mechanism problem.
Legal and Regulatory Status
The three approved DORAs—suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq)—are Schedule IV controlled substances in the United States. Schedule IV indicates low abuse potential relative to Schedule II–III substances. They are available by prescription only.
Orexin peptides (orexin-A, orexin-B) are not controlled substances. They are available as research-grade peptides from laboratory suppliers (e.g., Tocris, Bachem, Phoenix Pharmaceuticals) for institutional research use. They are not sold by consumer peptide vendors and are not marketed for self-administration.
No orexin receptor agonist is currently FDA-approved. TAK-861 (Takeda) and other candidates are in clinical development for narcolepsy type 1.
WADA does not currently prohibit orexin peptides or DORAs. The evolving discussion around sleep manipulation in athletics could change this.
Research Protocols and Formulation Considerations
FDA-Approved DORA Dosing
| Drug | Dose | Half-Life | Key Note |
|---|---|---|---|
| Suvorexant (Belsomra) | 10–20 mg at bedtime | ~12 hours | First-in-class. FDA capped dose at 20 mg (from 40 mg). |
| Lemborexant (Dayvigo) | 5–10 mg at bedtime | ~17–19 hours | Balanced OX1R/OX2R. Beat zolpidem head-to-head. |
| Daridorexant (Quviviq) | 25–50 mg at bedtime | ~8 hours | Shortest-acting DORA. Only one to show daytime improvement. |
General DORA prescribing guidance: - Take within 30 minutes of going to bed - Must allow ≥7 hours before planned awakening - Do not take with or immediately after a heavy meal (delays absorption) - Start at lowest effective dose - No dose adjustment needed for mild hepatic impairment - Avoid with strong CYP3A inhibitors (increases DORA exposure)
Dosing in Published Research
The following table summarizes dosing protocols for Orexin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Clinical Dosing
All DORA dosing is FDA-labeled and standardized. These are approved drugs, not research peptides.
| Drug | Indication | Dose | Route | Schedule |
|---|---|---|---|---|
| Suvorexant | Insomnia | 10–20 mg | Oral | Nightly at bedtime |
| Lemborexant | Insomnia | 5–10 mg | Oral | Nightly at bedtime |
| Daridorexant | Insomnia | 25–50 mg | Oral | Nightly at bedtime |
Orexin Peptide Research Dosing (Non-Therapeutic)
| Parameter | Detail |
|---|---|
| Route | IV infusion (human research); ICV (animal models) |
| Human IV dose | Orexin-A: 10–30 mcg/kg infused over 30–60 minutes (neuroendocrine studies) |
| Animal ICV dose | 0.1–10 mcg orexin-A or orexin-B |
| Context | Physiological research only — not therapeutic administration |
Dosing in Self-Experimentation Communities
WHY NO COMMUNITY DOSING SECTION?
Orexin is an FDA-approved prescription medication. Dosing is established by clinical guidelines and managed by prescribing physicians. Community “dosing protocols” for prescription medications can be dangerous and are not appropriate to present here. Consult your healthcare provider for dosing information.
Why This Section Is Nearly Empty
Orexin peptides are not part of the self-experimentation peptide community. They are not sold by consumer peptide vendors, do not cross the blood-brain barrier after peripheral injection, and would require intracerebroventricular delivery to achieve central effects—a neurosurgical procedure, not a self-injection protocol. The clinical orexin story is accessed through DORAs, which are prescription drugs obtained through standard medical channels. Biohacking discussions of orexin focus on the DORAs (comparing suvorexant vs. lemborexant vs. daridorexant for sleep quality and morning grogginess) rather than on the peptides themselves.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Orexin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Orexin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Orexin Compares
Orexin belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is orexin?
Orexin (also called hypocretin) is a pair of neuropeptides—orexin-A and orexin-B—produced by about 70,000 neurons in the lateral hypothalamus. These peptides are essential for maintaining wakefulness and stabilizing the boundary between sleep and wake states. Their loss causes narcolepsy.
Why does orexin have two names?
Two laboratories independently discovered the same peptides in 1998 and named them differently. Masashi Yanagisawa's group called them \u0022orexins\u0022 (appetite); Luis de Lecea's group called them \u0022hypocretins\u0022 (hypothalamic secretin-like). Both names are correct and used in different contexts. \u0022Orexin\u0022 is dominant in sleep medicine and pharmacology.
How do the insomnia drugs work?
Suvorexant, lemborexant, and daridorexant are dual orexin receptor antagonists (DORAs). They block both orexin receptor types (OX1R and OX2R) on brain cells that maintain wakefulness. This temporarily reduces the wake drive, allowing the sleep system to take over. They wear off by morning.
Are DORAs better than sleeping pills?
DORAs have several advantages over benzodiazepines and Z-drugs: they do not suppress breathing (safe in sleep apnea), produce more natural sleep architecture, have lower abuse potential, and cause less cognitive impairment. Lemborexant beat zolpidem head-to-head on sleep onset in a clinical trial. They also have disadvantages: they can cause sleep paralysis and vivid hallucinations in some people.
What is narcolepsy type 1?
Narcolepsy type 1 is a neurological disease caused by the autoimmune destruction of orexin-producing neurons. Patients lose more than 90% of these neurons, resulting in excessive daytime sleepiness, cataplexy (sudden loss of muscle tone during emotions), sleep paralysis, and hallucinations during sleep transitions. A spinal fluid test showing very low orexin-A (<110 pg/mL) diagnoses the condition.
Can I take orexin as a supplement?
No, in any practical sense. Orexin peptides do not cross the blood-brain barrier effectively after injection and are not available in oral form. The wake-promoting effects require orexin to reach specific brain regions, which currently is possible only through direct brain infusion in research settings. The therapeutic access to the orexin system comes through small-molecule drugs (DORAs), not the peptides themselves.
Will there be a cure for narcolepsy?
Orexin receptor agonists—drugs that activate orexin receptors to replace the missing signal—are in clinical development. TAK-994 showed dramatic wakefulness improvement but was halted for liver toxicity. Its successor TAK-861 is in Phase II trials. Gene therapy approaches to replace destroyed orexin neurons are in preclinical stages. A definitive cure may eventually come, but no product is approved yet.
How does orexin relate to other compounds in this cluster?
Orexin is interconnected with several Cluster J compounds. CRH activates orexin neurons during stress-induced arousal—explaining why stress causes insomnia. NPY opposes CRH and indirectly modulates orexin circuit activity. MCH is produced by neurons adjacent to orexin neurons in the lateral hypothalamus and promotes REM sleep, opposing orexin's wake-promoting role. The sleep-stress cluster is a network, not a collection of independent molecules.
Do DORAs affect dreaming?
Some patients report more vivid dreams or increased dream recall with DORAs, likely because orexin receptor blockade promotes more intact REM sleep than GABA-enhancing sleep aids. This is generally considered a reflection of improved sleep architecture rather than a side effect, though vivid nightmares can occur.
Is orexin related to obesity or appetite?
Orexin was originally named for its appetite-stimulating effects. Orexin neurons do integrate metabolic signals—they are activated by low glucose and inhibited by leptin and glucose. However, appetite regulation is secondary to arousal maintenance. Narcolepsy patients (who lack orexin) tend to gain weight, paradoxically—possibly because orexin also promotes physical activity and energy expenditure.
Can coffee or stimulants replace orexin?
Stimulants (caffeine, modafinil, amphetamines) promote wakefulness through different mechanisms—adenosine blockade, dopamine/norepinephrine release—and are used to treat narcolepsy symptoms. But they do not restore orexin signaling or stabilize the sleep-wake switch. They compensate for the missing orexin rather than replacing it, which is why narcolepsy patients on stimulants still experience cataplexy and state boundary instability.
Are DORAs safe long-term?
The Phase III trials included 3- to 12-month treatment periods showing maintained efficacy and tolerability. Long-term safety data beyond pivotal trials comes from open-label extensions and post-marketing surveillance. No unexpected long-term safety signals have emerged. The drugs do not show tolerance (increasing doses needed) at clinical doses over studied periods.
Summary of Key Findings
Orexin is the most clinically impactful neuropeptide discovery of the past three decades. In 1998, it was an unknown peptide named for appetite. By 2000, it was the proven cause of narcolepsy. By 2022, three drugs targeting its receptors were FDA-approved for insomnia—creating an entirely new pharmacological class. No other neuropeptide has traveled this path from discovery to approved drug class within a single generation.
The biology is elegant and definitive. Approximately 70,000 neurons in the lateral hypothalamus produce orexin-A and orexin-B, which stabilize the wake state by activating arousal centers throughout the brain. Destroy those neurons and you get narcolepsy—a disease of state boundary failure. Block their receptors and you get therapeutic sleep with more natural architecture than GABA-enhancing drugs. Activate their receptors and—in principle—you restore wakefulness to narcolepsy patients. Two of those three steps are clinical reality. The third is in development.
The DORA evidence base—nearly 5,000 insomnia patients across three Phase III programs—is among the strongest for any peptide-targeted therapy. The narcolepsy-orexin link—CSF orexin-A as a diagnostic biomarker with 99% specificity—is one of the most definitive in neurology. The orexin agonist pipeline, despite the TAK-994 setback, represents one of the most biologically rational drug development programs in sleep medicine.
Verdict Recapitulation
Evidence Tier 1 — Approved Drug. Three DORAs FDA-approved for insomnia. Definitive narcolepsy-orexin causal link. Active agonist pipeline.
Verdict: Strong Foundation. This is the neuropeptide success story—from discovery to disease mechanism to approved drug class in 24 years. The biology is unambiguous, the evidence is massive, and the clinical impact is still growing.
For readers considering Orexin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Orexin
Further Reading and Resources
If you want to go deeper on Orexin, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Orexin — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585 PubMed
- de Lecea L, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322–327 PubMed
- Nishino S, et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol. 2001;50(3):381–388 PubMed
- Herring WJ, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–148 PubMed
- Rosenberg R, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a Phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254 PubMed
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, Phase 3 trials (ZEST-1 and ZEST-2). Lancet Neurol. 2022;21(2):125–139 PubMed
- Lin L, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365–376 PubMed
- Saper CB, et al. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–1263 PubMed
DISCLAIMER
Orexin is an FDA-approved prescription medication. The information presented in this article is for educational purposes only. Off-label uses discussed here may not be supported by the same level of evidence as the approved indications. Always follow the guidance of your prescribing physician.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.